NZ601670A - Forms of rifaximin and uses thereof - Google Patents

Forms of rifaximin and uses thereof

Info

Publication number
NZ601670A
NZ601670A NZ601670A NZ60167011A NZ601670A NZ 601670 A NZ601670 A NZ 601670A NZ 601670 A NZ601670 A NZ 601670A NZ 60167011 A NZ60167011 A NZ 60167011A NZ 601670 A NZ601670 A NZ 601670A
Authority
NZ
New Zealand
Prior art keywords
iota
dry
rifaximin
polymorph
treating
Prior art date
Application number
NZ601670A
Other languages
English (en)
Inventor
Petinka Vlahova
Donglai Yang
Karen S Gushurst
Jeffrey S Stults
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of NZ601670A publication Critical patent/NZ601670A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NZ601670A 2010-02-19 2011-02-16 Forms of rifaximin and uses thereof NZ601670A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/708,836 US8486956B2 (en) 2008-02-25 2010-02-19 Forms of rifaximin and uses thereof
PCT/US2011/024981 WO2011103120A1 (en) 2010-02-19 2011-02-16 Forms of rifaximin and uses thereof

Publications (1)

Publication Number Publication Date
NZ601670A true NZ601670A (en) 2014-11-28

Family

ID=44483273

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ601670A NZ601670A (en) 2010-02-19 2011-02-16 Forms of rifaximin and uses thereof

Country Status (21)

Country Link
US (5) US8486956B2 (es)
EP (1) EP2536734B1 (es)
JP (2) JP2013520427A (es)
KR (1) KR20120140244A (es)
CN (2) CN102834398A (es)
AU (3) AU2011218258B2 (es)
BR (1) BR112012020863A2 (es)
CA (1) CA2790332A1 (es)
CR (1) CR20120449A (es)
EA (1) EA201270722A1 (es)
GE (2) GEP201706745B (es)
HK (1) HK1179608A1 (es)
IL (1) IL221299A (es)
MA (1) MA34058B1 (es)
MX (1) MX353827B (es)
MY (1) MY158992A (es)
NZ (1) NZ601670A (es)
SG (1) SG183188A1 (es)
TN (1) TN2012000414A1 (es)
WO (1) WO2011103120A1 (es)
ZA (1) ZA201206227B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3001996A (en) * 1957-02-08 1961-09-26 Hans S Mannheimer Sulfates and sulfonates of n-tertiary amino alkyl-carboxylic acid amides
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EA021176B1 (ru) 2008-02-25 2015-04-30 Сэликс Фармасьютиклз, Лтд. Полиморфная форма рифаксимина и её применение
WO2010040020A1 (en) 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20110035232A1 (en) * 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN103269587A (zh) * 2010-06-03 2013-08-28 萨利克斯药品有限公司 利福昔明的新形式及其用途
EP2582707A4 (en) * 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
MY165086A (en) * 2010-07-12 2018-02-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
EP2616044A1 (en) * 2010-09-13 2013-07-24 Cilpa Limited Pharmaceutical composition
CN103827122B (zh) 2011-02-11 2016-08-31 萨利克斯药品有限公司 利福昔明的形式及其用途
AU2012251385A1 (en) * 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
CA2854380A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (en) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2983647B1 (en) 2013-04-12 2020-09-09 Alfasigma S.p.A. Nsaid administration and related compositions, methods and systems
CN103509038B (zh) * 2013-09-30 2016-01-20 浙江思贤制药有限公司 一种新晶型利福昔明ζ及其制备方法
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015171493A1 (en) 2014-05-04 2015-11-12 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
JP6576953B2 (ja) 2014-05-12 2019-09-18 アルファシグマ ソシエタ ペル アチオニ リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
WO2016204474A2 (ko) * 2015-06-18 2016-12-22 주식회사대성미생물연구소 리팍시민 결정체를 포함하는 동물 장염 치료용 수의학적 조성물
PT3518924T (pt) 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Formas de dispersão sólidas de rifaximina

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US20020048610A1 (en) 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
DE102004004433A1 (de) 2004-01-28 2005-08-18 Trützschler GmbH & Co KG Vorrichtung an einer Spinnereimaschine, insbesondere Karde, Reiniger o. dgl., zum Aufziehen einer Garnitur auf eine Walze
ATE427311T1 (de) * 2004-07-22 2009-04-15 Cumbre Pharmaceuticals Inc (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
NZ575550A (en) 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2008273699A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
MY144578A (en) * 2007-07-27 2011-10-14 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
EA021176B1 (ru) 2008-02-25 2015-04-30 Сэликс Фармасьютиклз, Лтд. Полиморфная форма рифаксимина и её применение
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
SI2294012T1 (sl) 2008-05-07 2014-11-28 Salix Pharmaceuticals, Ltd. Dajanje ÄŤistila za ÄŤrevo in antibiotika za zdravljenje ÄŤrevesne bolezni
AU2009292615B2 (en) 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
KR20110107806A (ko) 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체
PE20121185A1 (es) 2009-10-27 2012-09-15 Lupin Ltd Dispersion solida de rifaximina
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CN103269587A (zh) * 2010-06-03 2013-08-28 萨利克斯药品有限公司 利福昔明的新形式及其用途
EP2582707A4 (en) * 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
CN103827122B (zh) * 2011-02-11 2016-08-31 萨利克斯药品有限公司 利福昔明的形式及其用途

Also Published As

Publication number Publication date
CR20120449A (es) 2012-11-29
WO2011103120A1 (en) 2011-08-25
AU2014246594B2 (en) 2016-09-15
EP2536734A4 (en) 2013-06-26
CA2790332A1 (en) 2011-08-25
US9034892B2 (en) 2015-05-19
AU2014246594A1 (en) 2014-10-30
SG183188A1 (en) 2012-09-27
HK1179608A1 (zh) 2013-10-04
AU2011218258B2 (en) 2015-11-05
JP2016094416A (ja) 2016-05-26
AU2016269529B2 (en) 2018-06-07
US20120316334A1 (en) 2012-12-13
US20100174064A1 (en) 2010-07-08
AU2011218258A1 (en) 2012-08-30
IL221299A (en) 2017-11-30
KR20120140244A (ko) 2012-12-28
US8569326B2 (en) 2013-10-29
CN102834398A (zh) 2012-12-19
AU2016269529A1 (en) 2017-01-05
BR112012020863A2 (pt) 2016-06-21
US8486956B2 (en) 2013-07-16
US20160200738A1 (en) 2016-07-14
US9546183B2 (en) 2017-01-17
ZA201206227B (en) 2018-12-19
TN2012000414A1 (en) 2014-01-30
EA201270722A1 (ru) 2013-03-29
MX2012009576A (es) 2012-12-05
JP2013520427A (ja) 2013-06-06
GEP20156230B (en) 2015-01-26
MA34058B1 (fr) 2013-03-05
US20140179916A1 (en) 2014-06-26
MY158992A (en) 2016-11-30
IL221299A0 (en) 2012-10-31
US20140141081A1 (en) 2014-05-22
EP2536734B1 (en) 2016-08-31
GEP201706745B (en) 2017-10-10
US9273066B2 (en) 2016-03-01
EP2536734A1 (en) 2012-12-26
MX353827B (es) 2018-01-31
CN105254647A (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
NZ601670A (en) Forms of rifaximin and uses thereof
NZ587099A (en) Forms of rifaximin and uses thereof
TW201612354A (en) Group 6 film forming compositions for vapor deposition of group 6 transition metal-containing films
MX353269B (es) Polimeros de organopolisiloxano.
EP2407521A4 (en) COATING COMPOSITION, COATING FILM, LAMINATE AND METHOD FOR PRODUCING THE LAMINATE
MX352892B (es) Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.
MX2016001444A (es) Organopolisiloxano cationico en bloque.
WO2012061187A3 (en) Volcanic ash-based drilling mud to overcome drilling challenges
PL2630108T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
WO2017201456A8 (en) Preparation of si-h containing iodosilanes via halide exchange reaction
MX2014015197A (es) Tratamiento y prevencion de la enfermedad cardiovascular y trombosis.
EP2584005A4 (en) METALLIC POLYSILOXANE COMPOSITION WITH COMMON METALS, METHOD OF MANUFACTURING THEREFOR AND USES THEREOF
CL2013000730A1 (es) Proceso para preparar compuestos derivados de dihidropteridinonas, moduladores de la quinasa tipo polo plk-1, útiles para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes; procesos de preparacion de compuestos intermediarios.
WO2011080751A3 (en) α4β2 NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
HK1182150A1 (en) Process for the coating of textiles
WO2013052195A3 (en) Rheology modified pretreatment compositions and associated methods of use
EP3329913A4 (en) Composition for inhibiting formation of snare complex, containing myricetin derivatives
PL2654758T3 (pl) Kompozycja zawierająca co najmniej dwa związki, która indukuje 2,3-dioksygenazę indolaminy (IDO) do leczenia zaburzenia autoimmunologicznego lub immunologicznego odrzucenia narządów
WO2010065586A3 (en) Preparation of capecitabine
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
WO2013057310A3 (en) Hybridization compositions and methods
WO2012006068A3 (en) Compounds for the inhibition of cellular proliferation
EP2441809A4 (en) ANTISALIZING COATING COMPOSITION, ANTISALISSURE PROTECTIVE FILM FORMED FROM THE COMPOSITION, COATED OBJECT HAVING THE PROTECTIVE FILM TO ITS SURFACE, AND ANTI-GLASS TREATMENT PROCESS BY FORMING THE PROTECTIVE FILM
IL208580A0 (en) Novel compounds derived from taurine, process of their preparation and phamaceutoical compositions containing these
MX2012001151A (es) Metodo para producir un revestimiento con el valor de brillo deseado.

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 3087381, SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVERALEIGH, NC 27615, US

Effective date: 20130814

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 FEB 2018 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS

Effective date: 20150601

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 FEB 2019 BY THOMSON REUTERS

Effective date: 20180112

LAPS Patent lapsed